July 30, 2023
1 min watch
Save
VIDEO: Ocuphire official previews company’s next steps
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
SEATTLE — In this Healio Video Perspective from OIS Retina, Ronil Patel, MS, discusses Ocuphire Pharma’s end-of-phase 2 FDA meeting planned for later this year.
Patel also previews two upcoming presentations on the safety and efficacy of APX3330, an oral drug candidate for diabetic retinopathy.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Patel reports being senior vice president of operations and business development at Ocuphire Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.